Selegiline may be toxic in presence of increased dopamine concentrations

BMJ 1996; 312 doi: https://doi.org/10.1136/bmj.312.7032.703b (Published 16 March 1996) Cite this as: BMJ 1996;312:703
  1. P H Yu*,
  2. C T Lai,
  3. A A Boulton*
  1. Professor Postdoctoral fellow Professor Neuropsychiatry Research Unit, Department of Psychiatry, University of Saskatchewan, Saskatoon, Saskatchewan, Canada S7N 5E4

    EDITOR,—In the trial carried out by the Parkinson's Disease Research Group of the United Kingdom levodopa plus selegiline seemed to offer no clinical benefit over levodopa alone, although less levodopa was required for the combined treatment.1 Mortality was significantly higher with the combined treatment. These findings contradict several earlier reports that selegiline, either alone or in combination, confers a beneficial effect in Parkinson's disease.

    During the course of Parkinson's disease a progressive degeneration of nigrostriatal dopaminergic neurones occurs, with the remaining neurones becoming further stressed …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription